作者: Mark T. Reding , Huiyun Wut , Mark Krampft , David K. Okita , Brenda M. Diethelm-Okita
DOI: 10.1007/978-1-4615-1277-6_11
关键词: Immunology 、 Bleeding episodes 、 Antibody 、 Oral tolerance 、 Acquired hemophilia 、 Complication 、 Severe bleeding 、 Medicine
摘要: Some hemophilia A patients, when treated with factor VIII (fVIII) products to control bleeding episodes, develop antibodies (Ab) surface domains of fVIII that are essential for its procoagulant function 1,3 Development inhibitors is a serious therapeutic complication affects 20 – 25% patients Individuals without congenital deficiency may also pathogenic autoimmune inhibitory Ab cause acquired hemophilia, rare yet severe disorder (4,5 ). FVIII high affinity IgG, and their synthesis requires the intervention specific CD4+ T helper cells.